CO6361993A2 - Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina - Google Patents

Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina

Info

Publication number
CO6361993A2
CO6361993A2 CO11064614A CO11064614A CO6361993A2 CO 6361993 A2 CO6361993 A2 CO 6361993A2 CO 11064614 A CO11064614 A CO 11064614A CO 11064614 A CO11064614 A CO 11064614A CO 6361993 A2 CO6361993 A2 CO 6361993A2
Authority
CO
Colombia
Prior art keywords
compounds
fluorophenoximethyl
piperidine
phenyl
formula
Prior art date
Application number
CO11064614A
Other languages
English (en)
Inventor
Lori Jean Patterson
Eric L Stangeland
Sheila Zipfel
Daniel D Long
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6361993A2 publication Critical patent/CO6361993A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La invención se refiere a los compuestos de la fórmula I:donde a, R1 y R3-6 son como se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo. Los compuestos de la fórmula I son inhibidores de la recaptación de serotonina y norepinefrina. La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos; métodos para usar dichos compuestos; y procesos e intermediarios para preparar dichos compuestos.
CO11064614A 2008-11-14 2011-05-25 Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina CO6361993A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14
PCT/US2009/064308 WO2010056941A1 (en) 2008-11-14 2009-11-13 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

Publications (1)

Publication Number Publication Date
CO6361993A2 true CO6361993A2 (es) 2012-01-20

Family

ID=41666409

Family Applications (2)

Application Number Title Priority Date Filing Date
CO11056556A CO6361988A2 (es) 2008-11-14 2011-05-09 Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
CO11064614A CO6361993A2 (es) 2008-11-14 2011-05-25 Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO11056556A CO6361988A2 (es) 2008-11-14 2011-05-09 Forma cristalina de un compuesto de 4-[2-(2-fluorofenoximetil)fenil]piperidina.

Country Status (29)

Country Link
US (22) US8247433B2 (es)
EP (3) EP2358675B9 (es)
JP (6) JP5529150B2 (es)
KR (3) KR101685186B1 (es)
CN (3) CN102216272B (es)
AR (3) AR074128A1 (es)
AU (3) AU2009313951B2 (es)
BR (3) BRPI0921593B8 (es)
CA (3) CA2742114C (es)
CL (2) CL2011001088A1 (es)
CO (2) CO6361988A2 (es)
CY (3) CY1113622T1 (es)
DK (3) DK2358674T3 (es)
ES (3) ES2396583T3 (es)
HK (3) HK1160448A1 (es)
HR (3) HRP20120897T1 (es)
IL (2) IL212230A (es)
MX (3) MX2011005088A (es)
MY (2) MY151211A (es)
NZ (2) NZ592543A (es)
PL (3) PL2358675T3 (es)
PT (3) PT2358674E (es)
RU (2) RU2515612C2 (es)
SG (1) SG171311A1 (es)
SI (3) SI2358676T1 (es)
SM (3) SMT201200063B (es)
TW (3) TWI461407B (es)
WO (3) WO2010056938A1 (es)
ZA (1) ZA201103495B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009313951B2 (en) 2008-11-14 2015-03-12 Theravance Biopharma R&D Ip, Llc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
CA2794127A1 (en) 2010-04-22 2011-10-27 Theravance, Inc. Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
IL288194B2 (en) * 2016-08-30 2024-03-01 Theravance Biopharma R& D Ip Llc [- 2 (- 6,4,2--trifluorophenoxymethyl) phenyl[piperidine for use in the treatment of neurogenic hypotension on standing
JP7252978B2 (ja) 2018-06-01 2023-04-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ２－（１－（ｔｅｒｔ－ブトキシカルボニル）ピペリジン－４－イル）安息香酸を調製するためのプロセス
US20230372318A1 (en) 2022-03-28 2023-11-23 Theravance Biopharma R&D Ip, Llc Methods for treating a subject having multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
AU763356C (en) * 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) * 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
PL1635828T3 (pl) 2003-04-04 2008-10-31 H Lundbeck As Pochodne 4-(2-fenyloksyfenylo)-piperydyny lub 1,2,3,6-tetrahydropirydyny jako inhibitory wychwytu zwrotnego serotoniny
MXPA05013960A (es) 2003-06-17 2006-02-24 Pfizer Nuevos compuestos.
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
US20070105870A1 (en) 2004-01-13 2007-05-10 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
US20070072859A1 (en) 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
CN101506164A (zh) 2006-08-23 2009-08-12 辉瑞产品公司 哌啶衍生物
EP2068867A2 (en) * 2006-09-27 2009-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CA2727174A1 (en) 2008-06-20 2010-01-21 Jiangao Song Aryl gpr119 agonists and uses thereof
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
AU2009313951B2 (en) 2008-11-14 2015-03-12 Theravance Biopharma R&D Ip, Llc 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
IL288194B2 (en) * 2016-08-30 2024-03-01 Theravance Biopharma R& D Ip Llc [- 2 (- 6,4,2--trifluorophenoxymethyl) phenyl[piperidine for use in the treatment of neurogenic hypotension on standing

Also Published As

Publication number Publication date
BRPI0921596B1 (pt) 2021-10-26
US9162982B2 (en) 2015-10-20
CL2011001088A1 (es) 2011-10-14
EP2358674B1 (en) 2013-01-02
CA2739992C (en) 2016-09-20
HK1160449A1 (en) 2012-08-17
US20140045892A1 (en) 2014-02-13
IL212452A0 (en) 2011-06-30
EP2358675B1 (en) 2012-10-03
WO2010056939A1 (en) 2010-05-20
TW201022206A (en) 2010-06-16
CY1113855T1 (el) 2016-07-27
BRPI0921593B8 (pt) 2021-05-25
US10206913B2 (en) 2019-02-19
CN102216272B (zh) 2014-02-05
TWI441810B (zh) 2014-06-21
SMT201200063B (it) 2013-01-14
MX2011005089A (es) 2011-07-29
RU2515612C2 (ru) 2014-05-20
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
US20200000792A1 (en) 2020-01-02
US8592596B2 (en) 2013-11-26
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
CA2742105A1 (en) 2010-05-20
TWI443087B (zh) 2014-07-01
HRP20120920T1 (hr) 2013-01-31
EP2358675A1 (en) 2011-08-24
BRPI0921595B1 (pt) 2020-10-13
JP2012508759A (ja) 2012-04-12
JP2012508760A (ja) 2012-04-12
US20180050024A1 (en) 2018-02-22
HK1160448A1 (en) 2012-08-17
EP2358676A1 (en) 2011-08-24
US8304433B2 (en) 2012-11-06
AU2009313949A1 (en) 2010-05-20
US10946007B2 (en) 2021-03-16
PT2358675E (pt) 2012-12-12
AU2009313948B2 (en) 2015-03-12
US20160022660A1 (en) 2016-01-28
ES2397247T3 (es) 2013-03-05
JP5529150B2 (ja) 2014-06-25
US20100125093A1 (en) 2010-05-20
JP2014101384A (ja) 2014-06-05
MY151229A (en) 2014-04-30
AR114965A2 (es) 2020-11-11
CN102216272A (zh) 2011-10-12
CA2739992A1 (en) 2010-05-20
PL2358676T3 (pl) 2013-03-29
SMT201200065B (it) 2013-03-08
BRPI0921593A2 (pt) 2015-08-18
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
EP2358676B1 (en) 2012-10-10
US11723900B2 (en) 2023-08-15
US20140057944A1 (en) 2014-02-27
JP5506813B2 (ja) 2014-05-28
JP2014098033A (ja) 2014-05-29
RU2503662C2 (ru) 2014-01-10
US20230201181A1 (en) 2023-06-29
IL212230A0 (en) 2011-06-30
EP2358675B9 (en) 2019-09-11
US11596624B2 (en) 2023-03-07
PL2358675T3 (pl) 2013-03-29
CA2742114C (en) 2016-09-13
MY151211A (en) 2014-04-30
US10946006B2 (en) 2021-03-16
SI2358674T1 (sl) 2013-04-30
CA2742105C (en) 2016-09-13
US9187423B2 (en) 2015-11-17
HRP20130300T1 (hr) 2013-04-30
CA2742114A1 (en) 2010-05-20
HK1160452A1 (en) 2012-08-17
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
TWI461407B (zh) 2014-11-21
US20130030020A1 (en) 2013-01-31
US20180289687A1 (en) 2018-10-11
TW201024264A (en) 2010-07-01
JP5598798B2 (ja) 2014-10-01
KR20110082197A (ko) 2011-07-18
PT2358674E (pt) 2013-03-05
HRP20120897T1 (hr) 2012-12-31
BRPI0921596A2 (pt) 2018-03-20
DK2358674T3 (da) 2013-04-08
AR074350A1 (es) 2011-01-12
CY1113622T1 (el) 2016-06-22
US10226454B2 (en) 2019-03-12
KR101656339B1 (ko) 2016-09-09
US20100125141A1 (en) 2010-05-20
EP2358674A1 (en) 2011-08-24
US20200316048A1 (en) 2020-10-08
BRPI0921595B8 (pt) 2021-05-25
US10722504B2 (en) 2020-07-28
CN102209712A (zh) 2011-10-05
US9675599B2 (en) 2017-06-13
MX2011005090A (es) 2011-09-06
ES2396583T3 (es) 2013-02-22
US20190142816A1 (en) 2019-05-16
CL2011001093A1 (es) 2011-09-02
KR101685186B1 (ko) 2016-12-09
SMT201300033B (it) 2013-05-06
AR074128A1 (es) 2010-12-22
US20140323735A1 (en) 2014-10-30
US20200316047A1 (en) 2020-10-08
CN102209712B (zh) 2016-04-06
US20100125092A1 (en) 2010-05-20
US20210290608A1 (en) 2021-09-23
KR101656338B1 (ko) 2016-09-09
TW201024263A (en) 2010-07-01
SI2358676T1 (sl) 2013-01-31
RU2011123875A (ru) 2012-12-20
US10034870B2 (en) 2018-07-31
AU2009313948A1 (en) 2010-05-20
US10441579B2 (en) 2019-10-15
PL2358674T3 (pl) 2013-06-28
DK2358676T3 (da) 2013-01-14
IL212230A (en) 2014-12-31
AU2009313949B2 (en) 2015-03-19
US8604058B2 (en) 2013-12-10
MX2011005088A (es) 2011-06-01
WO2010056941A1 (en) 2010-05-20
CO6361988A2 (es) 2012-01-20
US20130030185A1 (en) 2013-01-31
JP2012508761A (ja) 2012-04-12
CN102216271B (zh) 2013-09-25
US20180055830A1 (en) 2018-03-01
RU2011123890A (ru) 2012-12-20
JP2014139209A (ja) 2014-07-31
SI2358675T1 (sl) 2013-01-31
US20120277438A1 (en) 2012-11-01
KR20110082085A (ko) 2011-07-15
ES2401224T3 (es) 2013-04-17
PT2358676E (pt) 2012-12-06
DK2358675T3 (da) 2013-01-14
US10576073B2 (en) 2020-03-03
KR20110082196A (ko) 2011-07-18
AU2009313951B2 (en) 2015-03-12
BRPI0921593B1 (pt) 2021-05-04
US9073859B2 (en) 2015-07-07
ZA201103495B (en) 2012-01-25
AU2009313951A1 (en) 2010-05-20
NZ592543A (en) 2013-02-22
US20190134019A1 (en) 2019-05-09
US20160184288A1 (en) 2016-06-30
US8247433B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
CR20150045A (es) Inhibidores de hepatitis c
CO6511251A2 (es) Compuestos quimicos
CO6741228A2 (es) Inhibidores de la neprilisina
DOP2014000133A (es) Triazolopiridinas sustituidas
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
UY32884A (es) 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas
ECSP12012103A (es) Inhibidores de virus flaviviridae.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
BR112013028487A2 (pt) inibidores do vírus da hepatite c
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CL2009001346A1 (es) Compuestos derivados heterociclicos, inhibidores de la adn girasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion bacteriana.
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
ECSP11011045A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
MX2012000685A (es) Compuesto de 3-fenoximetilpirrolidina.
UY31824A (es) Nuevos compuestos
DOP2011000053A (es) Agentes antifungicos
AR085909A1 (es) Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras
EA201000611A1 (ru) 4,4-дизамещенные пиперидины
RU2014126321A (ru) Производное пароксетина

Legal Events

Date Code Title Description
FG Application granted